The antitumor immune response in HER-2 positive, metastatic breast cancer patients
详细信息 查看全文
- 作者：Zorica D Juranic (1)
Zora Neskovic-Konstantinovic (2)
Tatjana P Stanojkovic (1)
Zeljko Zizak (1)
Tatjana Srdic (1)
Nevenka Stanojevic-Bakic (1)
Dusanka Milosevic (1)
Danica Jovanovic (3) - 刊名：Journal of Translational Medicine
- 出版年：2005
- 出版时间：December 2005
- 年：2005
- 卷：3
- 期：1
- 全文大小：187KB
- 参考文献：1. Thomas E, Berner G: Prognostic and predictive implications of HER2 status for breast cancer patients. / Eur J Oncol Nurs 2000, 4:10鈥?7. CrossRef
2. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. / Proc Natl Acad Sci U S A 1992, 89:4285鈥?289. CrossRef
3. Baselga J, Albanell J, Molina MA, Arribas J: Mechanism of action of trastuzumab and scientific update. / Semin Oncol 2001, 28:4鈥?1. CrossRef
4. Kumar R, Yarmand-Bagheri R: The role of HER2 in angiogenesis. / Semin Oncol 2001, 28:27鈥?2. CrossRef
5. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. / Cancer Immunol Immunother 1993, 37:255鈥?63. CrossRef
6. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). / Semin Oncol 1999, 26:60鈥?0.
7. Devine DV: The regulation of complement on cell surfaces. / Transfus Med Rev 1991, 5:123鈥?31.
8. Juranic Z, Stanojevic-Bakic N, Neskovic-konstantinovic Z, Zizak Z, Stanojkovic T, Radulovic S, Milosevic D: The importance of antibody dependent cell-mediated cytotoxicity (ADCC) for breast cancer response to trastuzumab (Herceptin). / Archive of Oncology (Conference paper - XXXIX Annual meeting of the oncologists of Serbia 14鈥?5 November, 2002: Belgrade Yugoslavia) 2002, 162鈥?63.
9. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R: Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. / J Clin Pathol 2000, 53:374鈥?81. CrossRef
10. Ohno M, Abe T: Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). / J Immunol Methods 1991, 145:199鈥?03. CrossRef
11. Bell R, Verma S, Untch M, Cameron D, Smith I: Maximizing clinical benefit with trastuzumab. / Semin Oncol 2004, 31:35鈥?4. CrossRef
12. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. / Cancer Cell 2004, 6:117鈥?27. CrossRef
13. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. / Breast Cancer Res Treat 2000, 62:245鈥?52. CrossRef
14. Ferreira V, Molina MC, Valck C, Rojas A, Aguilar L, Ramirez G, Schwaeble W, Ferreira A: Role of calreticulin from parasites in its interaction with vertebrate hosts. / Mol Immunol 2004, 40:1279鈥?291. CrossRef
15. Andrin C, Pinkoski MJ, Burns K, Atkinson EA, Krahenbuhl O, Hudig D, Fraser SA, Winkler U, Tschopp J, Opas M, Bleackley RC, Michalak M: Interaction between a Ca2+-binding protein calreticulin and perforin, a component of the cytotoxic T-cell granules. / Biochemistry 1998, 37:10386鈥?0394. CrossRef
16. Fraser SA, Michalak M, Welch WH, Hudig D: Calreticulin, a component of the endoplasmic reticulum and of cytotoxic lymphocyte granules, regulates perforin-mediated lysis in the hemolytic model system. / Biochem Cell Biol 1998, 76:881鈥?87. CrossRef
17. Fraser SA, Karimi R, Michalak M, Hudig D: Perforin lytic activity is controlled by calreticulin. / J Immunol 2000, 164:4150鈥?155.
18. Cooley J, Takayama TK, Shapiro SD, Schechter NM, Remold-O'Donnell E: The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. / Biochemistry 2001, 40:15762鈥?5770. CrossRef
19. Schimmer AD, Pedersen IM, Kitada S, Eksioglu-Demiralp E, Minden MD, Pinto R, Mah K, Andreeff M, Kim Y, Suh WS, Reed JC: Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. / Cancer Res 2003, 63:1242鈥?248. - 作者单位：Zorica D Juranic (1)
Zora Neskovic-Konstantinovic (2)
Tatjana P Stanojkovic (1)
Zeljko Zizak (1)
Tatjana Srdic (1)
Nevenka Stanojevic-Bakic (1)
Dusanka Milosevic (1)
Danica Jovanovic (3)
1. Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia and Montenegro
2. Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia and Montenegro
3. Department of Pathology, Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia and Montenegro
文摘
The aim of this study was to determine the basis for anti-tumor immune reactivity observed in patients with human epidermal growth factor receptor-2 (HER-2) (3+) breast carcinoma using an in vitro model in which the role of the HER-2-specific monoclonal antibody Herceptin was also investigated. Patients with metastatic breast cancer who had their primary tumor resected were included in this study. Peripheral blood mononuclear cell (PBMC)-dependent cytotoxicity in the presence or absence of Herceptin were assessed using the survival of target breast adenocarcinoma MDA-MB-361 cells as a parameter in a (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) test. We observed a significant increase in PBMC-dependent cytotoxicity when autologous serum was introduced in the assay. Furthermore, the addition of Herceptin significantly increases their cytotoxicity. These data suggest that autologous serum constitutively contains factors that might affect PBMC-dependent cytotoxic activity against HER-2 positive cancer cells.